Lonza to invest USD 150 million in Genome Valley, Hyderabad Bio Asia 2010 announced

Lonza to invest USD 150 million in Genome Valley, Hyderabad Bio Asia 2010 announced

Global bio-pharmaceutical giant, Switzerland-based Lonza, today announced to invest USD 150 million (Rs 750 crores, approx.) for two major projects inGenomeValleylocated at the outskirts of Hyderabad.

Email Print Download PDF Add to Google RSS twitter Hyderabad, Andhra Pradesh, IND, 2009-05-20 19:00:00 (IndiaPRwire.com) Downloads
No files attached
Global bio-pharmaceutical giant, Switzerland-based Lonza, today announced to invest USD 150 million (Rs 750 crores, approx.) for two major projects inGenomeValleylocated at the outskirts of Hyderabad. Lonza Group (SWX: LONN) is a 100-year-old USD 2.5 billion Swiss chemical and biotechnology company based at Basel.

Chairman and Managing Director of Andhra Pradesh Industrial Infrastructure Corporation, Mr. BP Acharya, announced the investment during the India Evening session held at India Pavilion at the international biotech conference BIO inAtlanta,USA.

Concurrent with this announcement, Mr. Acharya released copies of the allotment letters issued to M/s Lonza in the Genome Valley SEZ and Phase II Biotech Park for R&D and bio-pharmaceutical manufacturing facility.

"This is one of the largest investments in recent times in the bio-pharmaceutical sector inIndiaand marks the emergence ofIndia, in general, andGenomeValley, in particular, as a preferred destination for global bio-pharmaceutical companies," said Mr. Acharya.

"This is an achievement of Bio Asia, the global bio-business forum, andGenomeValleyto draw such companies as Lonza toHyderabad. The ultimate motive of Bio Asia is knowledge sharing and business development. We are committed to such developments and hope that we will be able to strike such chords of success in Bio Asia 2010," said Dr. BS Bajaj, Secretary General, FABA. Dr. Bajaj announced the launch of Bio Asia 2010 to be held atHyderabadfrom February 3rdto February 6th2010. The brochure and CD for Bio Asia 2010 were released by Mrs. Banashri Bose Harrison, Minister (Commerce), Embassy of India, US. Mr. S. Suryanarayana, Director General, ABLE; Dr. S. Langer, Director Biotechnology ofJohns Hopkins University,USA; were among the others present at the occasion.

Mr. Stefen Borgas, CEO of Lonza, had visitedGenomeValleyduring Bio Asia 2009. Mr. Borgas was impressed by the talent pool, scientific culture and the infrastructure facilities available at theGenomeValley- the first world-class biotechnology cluster inIndia. "I think the Indian industry is positioned very well, having built up a significant pool of scientists servicing the global pharmaceutical and biotechnology industry," Mr. Borgas had said.

Lonza has chalked out the development of its facility in two phases as enumerated below:

Phase I (Operational 2011 to 2013):

R&D labs for 100+ staff. Facility for tissue/cell isolation, cell culture and expression techniques, bio services, labs for biologics and bioinformatics.
Microbiological application labs and formulation development for microbial control for injectables.
Small-scale multi-purpose manufacturing plant for biopharmaceuticals.
Small-scale bio-therapeutic media manufacturing plant.
Phase II (Operational 2014 to 2015):

Expanded media manufacturing capacity for bio-therapeutic media.
Additional R&D lab capacity for biologics (200 people approx.).
Expanded large-scale manufacturing plant for biopharmaceuticals.
Additional support functions.

- End -

About Lonza


Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers' needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Bio-pharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bio-products which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.


Lonza is headquartered inBasel,Switzerlandand is listed on the SWX Swiss Ex-change. In 2007, Lonza had sales of CHF 2.87 billion. Further information can be found atwww.lonza.com.

About Bio Asia 2010


BioAsiais an annual international biotech event, active since 2004 assisting biotech and pharmaceutical companies around the globe to create new business partnerships, academic and industrial collaborations and for exploring and sharing resources.


The seventh edition of the Bio Asia, Bio Asia 2010: The Global Bio-business Forum is all set to be held atHyderabadfrom February 3-6, 2010. With the tremendous response received from the Biotech/ Biopharma/ Agribiotech industries, it has been decided to lay major emphasis in the Bio-partnering and Tradeshow during Bio Asia 2010. The event will comprise of conference, tradeshow and B2B Platform.

Suggested Articles

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.